Armata Pharmaceuticals, Inc.
ARMP · XNYSCIK 921114fmd_18S4KTRVXKD55FXJFHGN5EASPTManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 55 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | 6 | 3 | 8 | 10 | 14 | 20 | 35 | 34 | 34 | 24 |
| Total operating expenses | 24 | 16 | 18 | 20 | 22 | 28 | 42 | 45 | 48 | 42 |
| Operating income | (23) | (16) | (18) | (20) | (22) | (24) | (37) | (41) | (42) | (37) |
| Interest expense | 0 | – | 1 | 1 | 1 | 0 | 0 | 3 | – | – |
| Interest and investment income | – | – | 0 | 0 | 0 | 0 | 0 | 0 | – | – |
| Other non-operating income (expense) | 4 | 2 | 1 | 0 | (1) | 1 | 0 | (28) | 24 | (137) |
| Income before taxes | (19) | (14) | (17) | (19) | (22) | (23) | (0) | (69) | (19) | (174) |
| Income tax expense | (1) | (1) | (0) | – | – | – | – | – | – | – |
| Net income from continuing operations | (19) | (13) | (16) | – | – | – | – | – | – | – |
| Net income | (19) | (13) | (17) | (19) | (22) | (23) | (37) | (69) | (19) | (174) |
| Net income to common shareholders | (24) | (13) | (17) | (19) | (22) | – | – | (69) | (19) | (174) |